Combination Antihypertensive Therapy Challenges the Dogma of Poor Drug Tolerability

Recent data challenge the long-standing perception that intensifying blood pressure–lowering therapy worsens adverse effects, a key barrier to achieving guideline-directed targets.

A large network meta-analysis of randomized trials evaluated whether antihypertensive combinations increase treatment discontinuation compared with monotherapy or placebo, addressing a critical gap between perceived and true drug tolerability.

Key Insight: Regimens containing angiotensin receptor blockers (ARBs)—particularly ARB + calcium channel blocker (CCB) combinations—demonstrated lower discontinuation rates than placebo, suggesting that some therapies may improve overall symptom burden rather than worsen it.

Notably, CCB-based regimens and certain combinations (e.g., beta-blocker + thiazide) showed higher discontinuation rates, reinforcing that drug class selection remains clinically relevant despite similar BP-lowering efficacy across agents.

A central concept is “over attribution” of adverse events, where symptoms like dizziness or fatigue are incorrectly blamed on medications, paralleling observations in statin intolerance, and contributing to undertreatment.

Importantly, guideline-directed therapy still prioritizes comorbidity-specific benefits (e.g., ACE inhibitors/ARBs in HFrEF or diabetic nephropathy) over tolerability alone, emphasizing individualized treatment.

Clinical Takeaway: Early combination therapy, especially ARB-based regimens, may improve both BP control and adherence, challenging the reflexive preference for monotherapy.

Practice Points:

• ARB + CCB combinations may optimize tolerability and adherence
• Do not overattribute nonspecific symptoms to antihypertensives
• Prioritize comorbidity-driven drug selection
• Consider upfront combination therapy in most patients

Patient Scenario:
A 58-year-old with stage 2 hypertension (160/100 mm Hg) reports fatigue on prior monotherapy and is reluctant to restart treatment.

Switching to low-dose ARB + CCB leads to improved BP (128/78 mm Hg) with no perceived side effects, illustrating how combination therapy can enhance both efficacy and tolerability.

References:

• Wang N et al. JAMA. 2026.
• McDermott MM, Persell SD. JAMA. 2026.